Page 1647 - Williams Hematology ( PDFDrive )

1622 Part XI: Malignant Lymphoid Diseases Chapter 97: Hodgkin Lymphoma 1623

193. Nademanee A, O’Donnell MR, Snyder DS, et al: High-dose chemotherapy with or 218. Weihrauch MR, Manzke O, Beyer M, et al: Elevated serum levels of CC thymus and
without total body irradiation followed by autologous bone marrow and/or periph- activation-related chemokine (TARC) in primary Hodgkin’s disease: Potential for a
eral blood stem cell transplantation for patients with relapsed and refractory Hodgkin’s prognostic factor. Cancer Res 65:5516–5519, 2005.
disease: Results in 85 patients with analysis of prognostic factors. Blood 85:1381–1390, 219. Brink AA, Oudejans JJ, van den Brule AJ, et al: Low p53 and high bcl-2 expression in
1995. Reed-Sternberg cells predicts poor clinical outcome for Hodgkin’s disease: Involvement
194. Stiff PJ, Unger JM, Forman SJ, et al: The value of augmented preparative regimens com- of apoptosis resistance? Mod Pathol 11:376–383, 1998.
bined with an autologous bone marrow transplant for the management of relapsed or 220. Montalban C, Garcia JF, Abraira V, et al: Influence of biologic markers on the outcome
refractory Hodgkin disease: A Southwest Oncology Group phase II trial. Biol Blood of Hodgkin’s lymphoma: A study by the Spanish Hodgkin’s Lymphoma Study Group. J
Marrow Transplant 9:529–539, 2003. Clin Oncol 22:1664–1673, 2004.
195. Fung HC, Stiff P, Schriber J, et al: Tandem autologous stem cell transplantation for 221. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, et al: BCL-2 expression in Hodgkin
patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in
Marrow Transplant 13:594–600, 2007. patients treated with ABVD or equivalent regimens. Blood 100:3935–3941, 2002.
196. Smith EP, Li H, Friedberg J, et al: SWOG S0410/BMT CTN 0703: A phase II trial of 222. Vassallo J, Metze K, Traina F, et al: The prognostic relevance of apoptosis-related pro-
tandem autologous stem cell transplantation for patients with primary progressive or teins in classical Hodgkin’s lymphomas. Leuk Lymphoma 44:483–488, 2003.
recurrent Hodgkin lymphoma. Blood 124 (ASH Annual Meeting Abstracts): 676, 2014. 223. Portlock CS, Donnelly GB, Qin J, et al: Adverse prognostic significance of CD20 pos-
197. Moskowitz CH, Bertino JR, Glassman JR, et al: Ifosfamide, carboplatin, and etoposide: itive Reed-Sternberg cells in classical Hodgkin’s disease. Br J Haematol 125:701–708,
A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization 2004.
regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol 224. Tzankov A, Krugmann J, Fend F, et al: Prognostic significance of CD20 expression in
17:3776–3785, 1999. classical Hodgkin lymphoma: A clinicopathological study of 119 cases. Clin Cancer Res
198. Bartlett NL, Niedzwiecki D, Johnson JL, et al: Gemcitabine, vinorelbine, and pegylated 9:1381–1386, 2003.
liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: 225. Diepstra A, van Imhoff GW, Karim-Kos HE, et al: HLA class II expression by Hodgkin
CALGB 59804. Ann Oncol 18:1071–1079, 2007. Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin’s lym-
199. Kuruvilla J, Keating A, Crump M: How I treat relapsed and refractory Hodgkin lym- phoma. J Clin Oncol 25:3101–3108, 2007.
phoma. Blood 117:4208–4217, 2011. 226. Diepstra A, van Imhoff GW, Schaapveld M, et al: Latent Epstein-Barr virus infection of
200. Burroughs LM, O’Donnell PV, Sandmaier BM, et al: Comparison of outcomes of HLA- tumor cells in classical Hodgkin’s lymphoma predicts adverse outcome in older adult
matched related, unrelated, or HLA-haploidentical related hematopoietic cell trans- patients. J Clin Oncol 27:3815–3821, 2009.
plantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin 227. Keegan TH, Glaser SL, Clarke CA, et al: Epstein-Barr virus as a marker of survival after
lymphoma. Biol Blood Marrow Transplant 14:1279–1287, 2008. Hodgkin’s lymphoma: A population-based study. J Clin Oncol 23:7604–7613, 2005.
201. Sureda A, Robinson S, Canals C, et al: Reduced-intensity conditioning compared with 228. Alvaro T, Lejeune M, Salvado MT, et al: Outcome in Hodgkin’s lymphoma can be pre-
conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s dicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer
lymphoma: An analysis from the Lymphoma Working Party of the European Group for Res 11:1467–1473, 2005.
Blood and Marrow Transplantation. J Clin Oncol 26:455–462, 2008. 229. Alvaro-Naranjo T, Lejeune M, Salvado-Usach MT, et al: Tumor-infiltrating cells as a
202. Horning S, Bartlett NL, Breslin S: Results of a prospective phase II trial of limited and prognostic factor in Hodgkin’s lymphoma: A quantitative tissue microarray study in a
extended rituximab treatment in nodular lymphocyte predominant Hodgkin’s disease large retrospective cohort of 267 patients. Leuk Lymphoma 46:1581–1591, 2005.
(NLPHD). ASH Annu Meet Abstr 110:644, 2007. 230. Kelley TW, Pohlman B, Elson P, et al: The ratio of FOXP3+ regulatory T cells to gran-
203. Forero-Torres A, Leonard JP, Younes A, et al: A Phase II study of SGN-30 (anti-CD30 zyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and
mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol is independent of bcl-2 and MAL expression. Am J Clin Pathol 128:958–965, 2007.
146:171–179, 2009. 231. Steidl C, Lee T, Shah SP, et al: Tumor-associated macrophages and survival in classic
204. Illidge T, Bouabdallah R, Chen R, et al: Allogeneic transplant following brentuximab Hodgkin’s lymphoma. N Engl J Med 362:875–885, 2010.
vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic 232. Scott DW, Chan FC, Hong F, et al: Gene expression-based model using formalin-fixed
anaplastic large cell lymphoma. Leuk Lymphoma 56:703–710, 2015. paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodg-
205. Gopal AK, Ramchandren R, O’Connor OA, et al: Safety and efficacy of brentuximab kin lymphoma. J Clin Oncol 31:692–700, 2013.
vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. 233. Hoppe RT: Hodgkin’s disease: Complications of therapy and excess mortality. Ann
Blood 120:560–568, 2012. Oncol 8 Suppl 1:115–118, 1997.

205a. Ansell SM, Lesokhin AM, Borrello I, et al: PD-1 blockade with nivolumab in relapsed 234. Ng AK, Bernardo MP, Weller E, et al: Long-term survival and competing causes of
or refractory Hodgkin’s lymphoma. N Engl J Med 372:311-319, 2015. death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin
206. Brenner H, Gondos A, Pulte D: Survival expectations of patients diagnosed with Hodg- Oncol 20:2101–2108, 2002.
kin’s lymphoma in 2006–2010. Oncologist 14:806–813, 2009. 235. Arseneau JC, Sponzo RW, Levin DL, et al: Nonlymphomatous malignant tumors com-
207. Moccia AA, Donaldson J, Chhanabhai M, et al: International Prognostic Score in plicating Hodgkin’s disease. Possible association with intensive therapy. N Engl J Med
advanced-stage Hodgkin’s lymphoma: Altered utility in the modern era. J Clin Oncol 287:1119–1122, 1972.
30:3383–3388, 2012. 236. Kaldor JM, Day NE, Clarke EA, et al: Leukemia following Hodgkin’s disease. N Engl J
208. Brenner H, Gondos A, Pulte D: Ongoing improvement in long-term survival of patients Med 322:7–13, 1990.
with Hodgkin disease at all ages and recent catch-up of older patients. Blood 111: 237. Koontz MZ, Horning SJ, Balise R, et al: Risk of therapy-related secondary leukemia
2977–2983, 2008. in Hodgkin lymphoma: The Stanford University experience over three generations of
209. Evens AM, Sweetenham JW, Horning SJ: Hodgkin lymphoma in older patients: An clinical trials. J Clin Oncol 31:592–598, 2013.
uncommon disease in need of study. Oncology (Williston Park) 22:1369–1379, 2008. 238. Schonfeld SJ, Gilbert ES, Dores GM, et al: Acute myeloid leukemia following Hodgkin lym-
210. Ballova V, Ruffer JU, Haverkamp H, et al: A prospectively randomized trial carried phoma: A population-based study of 35,511 patients. J Natl Cancer Inst 98:215–218, 2006.
out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced 239. Tucker MA, Coleman CN, Cox RS, et al: Risk of second cancers after treatment for
Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9el- Hodgkin’s disease. N Engl J Med 318:76–81, 1988.
derly). Ann Oncol 16:124–131, 2005. 240. van Leeuwen FE, Somers R, Taal BG, et al: Increased risk of lung cancer, non-Hodgkin’s
211. Advani R, Maeda L, Lavori P, et al: Impact of positive positron emission tomography on lymphoma, and leukemia following Hodgkin’s disease. J Clin Oncol 7:1046–1058, 1989.
prediction of freedom from progression after Stanford V chemotherapy in Hodgkin’s 241. Rueffer U, Josting A, Franklin J, et al: Non-Hodgkin’s lymphoma after primary Hodg-
disease. J Clin Oncol 25:3902–3907, 2007. kin’s disease in the German Hodgkin’s Lymphoma Study Group: Incidence, treatment,
212. Sher DJ, Mauch PM, Van Den Abbeele A, et al: Prognostic significance of mid- and and prognosis. J Clin Oncol 19:2026–2032, 2001.
post-ABVD PET imaging in Hodgkin’s lymphoma: The importance of involved-field 242. Schmitz R, Renne C, Rosenquist R, et al: Insights into the multistep transformation
radiotherapy. Ann Oncol 20:1848–1853, 2009. process of lymphomas: IgH-associated translocations and tumor suppressor gene
213. Moskowitz CH, Matasar MJ, Zelenetz AD, et al: Normalization of pre-ASCT, FDG- mutations in clonally related composite Hodgkin’s and non-Hodgkin’s lymphomas.
PET imaging with second-line, non-cross-resistant, chemotherapy programs improves Leukemia 19:1452–1458, 2005.
event-free survival in patients with Hodgkin lymphoma. Blood 119:1665–1670, 2012. 243. Huang JZ, Weisenburger DD, Vose JM, et al: Diffuse large B-cell lymphoma arising in
214. Moskowitz CH, Nimer SD, Zelenetz AD, et al: A 2-step comprehensive high-dose che- nodular lymphocyte predominant Hodgkin lymphoma: A report of 21 cases from the
moradiotherapy second-line program for relapsed and refractory Hodgkin disease: Anal- Nebraska Lymphoma Study Group. Leuk Lymphoma 45:1551–1557, 2004.
ysis by intent to treat and development of a prognostic model. Blood 97:616–623, 2001. 244. Bhatia S, Robison LL, Oberlin O, et al: Breast cancer and other second neoplasms after
215. Moskowitz C: Risk-adapted therapy for relapsed and refractory lymphoma using ICE childhood Hodgkin’s disease. N Engl J Med 334:745–751, 1996.
chemotherapy. Cancer Chemother Pharmacol 49 Suppl 1:S9–S12, 2002. 245. Hancock SL, Donaldson SS, Hoppe RT: Cardiac disease following treatment of Hodg-
216. Casasnovas RO, Mounier N, Brice P, et al: Plasma cytokine and soluble receptor signa- kin’s disease in children and adolescents. J Clin Oncol 11:1208–1215, 1993.
ture predicts outcome of patients with classical Hodgkin’s lymphoma: A study from the 246. Shapiro CL, Mauch PM: Radiation-associated breast cancer after Hodgkin’s disease:
Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 25:1732–1740, 2007. Risks and screening in perspective. J Clin Oncol 10:1662–1665, 1992.
217. Niens M, Visser L, Nolte IM, et al: Serum chemokine levels in Hodgkin lymphoma 247. Swerdlow AJ, Barber JA, Hudson GV, et al: Risk of second malignancy after Hodgkin’s
patients: Highly increased levels of CCL17 and CCL22. Br J Haematol 140:527–536, disease in a collaborative British cohort: The relation to age at treatment. J Clin Oncol
2008. 18:498–509, 2000.

Kaushansky_chapter 97_p1603-1624.indd 1622 9/18/15 11:12 PM